<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 9 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page8.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=9">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 9 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 9</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=9"><img src="../thumb/9.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>6a / 2020-04

   Drugs In Sport


   Below is an extract of the list of banned drugs as detailed by the IOC effective from 1 January 2019. It is valid until further notice. The list represents different doping
   classes to illustrate the doping definition. No substances belonging to the banned classes may be used even if they are not listed as examples. For this reason, the
   term "and related substances" is introduced. This term describes drugs that are related to the class by their pharmacological actions or chemical structure.
     Only products that are permitted for use in sport competition, be it subject to certain restrictions, are flagged by the use of codes alongside the relevant trade name
   or presentation. Product listings of medicines which may be classified as "banned in and out of competition" carry  no reference to their use in sport.
   [P/S]   This medicine or presentation contains ingredients not banned by the IOC.
   [PWR]   This medicine or presentation contains ingredients where use is subject to certain restrictions.
   [N/P/S]   This presentation within a product range contains substances not permitted in and out of competition and that presentation and the
           trade name are flagged accordingly.
   [N/P/S in C]  This preparation contains ingredients that are prohibited in competition only and the trade name is flagged accordingly.
   • Listed substances are examples but not limited to, and also include analogues of substances and related substances.
   • All prohibited substances shall be considered as "Specified Substances" except Substances in classes S1, S2, S4.4, S4.5 and S6.a, and Prohibited
       Methods M1, M2 and M3.
         Substances and methods   •  oxymesterone                 EPO-mimetic agents and their constructs
                                                                  (e.g. CNTO-530, peginesatide).
          prohibited at all times   •  oxymetholone             1.2  Hypoxia-inducible factor (HIF) acti vating
                                •  prostanozol
        (in and out of competition)  •  quinbolone                agents, e.g. Argon; Cobalt; Dapro dustat; Moli-
                                •  stanozolol                     dustat; Roxadustat (FG-4592); Vadadustat; Xenon.
   PROHIBITED SUBSTANCES        •  stenbolone                   1.3  GATA inhibitors, e.g.K-11706.
   S0  NON-APPROVED SUBSTANCES  •  1-testosterone               1.4  TGF-beta (TGF-β) inhibitors, e.g. Luspa-
                                                                  tercept; Sota tercept.
   Any pharmacological substance which is not   •  tetrahydrogestrinone
   addressed by any of the subsequent sections of the   •  trenbolone  1.5  Innate repair receptor agonists, e.g.
   List and with no current approval by any governmental      and other substances with a similar chemical   Asialo EPO; Carba  mylated EPO (CEPO).
   regulatory health authority for human therapeutic use   structure or similar biological effect(s)  2.  Peptide Hormones and their Releasing Factors,
   (e.g. drugs under pre-clinical or clinical development   b  Endogenous** AAS and their metabolites   2.1  Chorionic Gonadotrophin (CG) and
   or discontinued, designer drugs, substances approved   and isomers when administered exogenously,   Luteinising Hor mone (LH) and their
   only for veterinary use) is prohibited at all times.  including but not limited to:  releasing factors in males, e.g. Busere-
                                •  4-Androstenediol               lin, deslorelin, gonadorelin, goserelin,
   S1  ANABOLIC AGENTS          •  4-Hydroxytestosterone          leuprorelin, nafarelin and triptorelin,
   Anabolic agents are prohibited.  •  5-Androstenedione        2.2  Corticotrophins and their releasing
   1.  Anabolic androgenic steroids (AAS)  •  7a-hydroxy-DHEA     factors, e.g. Corticorelin;
   *  Exogenous: refers to a substance which is not  •  7b-hydroxy-DHEA  2.3  Growth Hormone (GH), its fragments
     ordinarily produced by the body naturally.  •  7-keto-DHEA   and releasing factors, including, but not
   **  Endogenous: refers to a substance which is  •  19-norandrostenediol  limi ted to: Growth Hormone fragments,
     ordinarily produced by the body naturally.  •  19-norandrostenedione  e.g. AOD-9604 and hGH 176-191; Growth
   a  Exogenous* AAS including  •  androstanolone                 Hormone Releasing Hormone (GHRH)
   •  1-androstenediol          •  androstenediol                 and its ana  logues, e.g. CJC-1293, CJC-1295,
   •  1-androstenedione         •  androstenedione                sermorelin and tesamorelin; Growth Hormone
   •  1-androsterone            •  boldenone                      Secretagogues (GHS), e.g. leno morelin (ghrelin)
   •  bolasterone               •  boldione                       and its mimetics, e.g. anamorelin, ipamorelin,
   •  calusterone               •  epiandrosterone                macimorelin and tabimorelin; GH-Releasing
   •  clostebol                 •  epi-dihydrotestosterone        Peptides (GHRPs), e.g. alexamorelin, GHRP-1,
   •  danazol                   •  epitestosterone                GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5,
   •  dehydrochlormethyltestosterone  •  nandrolone               GHRP-6, and examorelin.
   •  desoxymethyltestosterone  •  prasterone                3.  Growth Factors and Growth Factor Modu lators,
   •  drostanolone              •  testosterone                 including, but not limited to: Fibroblast Growth
   •  ethylestrenol                                             Factors (FGFs); Hepatocyte Growth Factor
   •  fluoxymesterone           2.  Other anabolic agents       (HGF); Insulin-like Growth Factor-1 (IGF-1)
   •  formebolone                  including but not limited to:  and its analogues; Mechano Growth Factors
   •  furazabol                 •  clenbuterol                  (MGFs); Platelet-Derived Growth Factor (PDGF);
   •  gestrinone                •  selective androgen receptor modulators (SARMs,   Thymosin-ß4 and its deriva tives e.g. TB-500;
   •  mestanolone                  e.g. andarine, LGD-4033, enobosarm (ostarine)   Vascular-Endothelial Growth Factor (VEGF).
   •  mesterolone                  and RAD140).                   Additional growth factors or growth factor
   •  metenolone                •  tibolone                     modulators affecting muscle, tendon or ligament
   •  methandienone             •  zeranol                      protein synthesis/ degradation, vascularisation,
   •  methandriol               •  zilpaterol.                  energy utilisation, regenera tive capacity or fibre
   •  methasterone                                              type switching.
   •  methyldienolone           S2  PEPTIDE HORMONES, GROWTH FACTORS,
   •  methyl-1-testosterone        RELATED SUBSTANCES AND MIMETICS  S3  BETA-2-AGONISTS
   •  methylnortestosterone     The following substances, and other substances  All selective and non selective beta-2 agonists
   •  methyltestosterone        with simi lar chemical structure or similar biological  including all optical isomers are prohibited.
   •  metribolone               effect(s), are prohibited:   Including, but not limited to:
   •  mibolerone                1.  Erythropoietins (EPO) and agents affecting  •  Fenoterol;
   •  norboletone                  erythro poiesis, including, but not limited to:  •  Formoterol;
   •  norclostebol                 1.1  Erythropoietin-Receptor Agonists, e.g.  •  Higenamine;
   •  norethandrolone                Darbe poetins (dEPO); Erythropoietins (EPO);  •  Indacaterol;
   •  oxabolone                      EPO based constructs [EPO-Fc, methoxy  •  Olodaterol;
   •  oxandrolone                    polyethylene glycol-epoetin beta (CERA)];  •  Procaterol;
                     MIMS subscription call centre office hours are from
                                 Monday to Friday 08:00-16:00
                Please feel free to contact: Riëtte (011) 280-5856; Sean (011) 280-5533</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page8.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page4.html">4</a>&nbsp;&nbsp;&nbsp;<a href="page5.html">5</a>&nbsp;&nbsp;&nbsp;<a href="page6.html">6</a>&nbsp;&nbsp;&nbsp;<a href="page7.html">7</a>&nbsp;&nbsp;&nbsp;<a href="page8.html">8</a>&nbsp;&nbsp;&nbsp;<a href="page9.html">9</a>&nbsp;&nbsp;&nbsp;<a href="page10.html">10</a>&nbsp;&nbsp;&nbsp;<a href="page11.html">11</a>&nbsp;&nbsp;&nbsp;<a href="page12.html">12</a>&nbsp;&nbsp;&nbsp;<a href="page13.html">13</a>&nbsp;&nbsp;&nbsp;<a href="page14.html">14</a>
             </td>
             <td width="35%"><a href="page10.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page10.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
